These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18484710)

  • 1. Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.
    Xie P; Williams DS; Atilla-Gokcumen GE; Milk L; Xiao M; Smalley KS; Herlyn M; Meggers E; Marmorstein R
    ACS Chem Biol; 2008 May; 3(5):305-16. PubMed ID: 18484710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β.
    Atilla-Gokcumen GE; Di Costanzo L; Meggers E
    J Biol Inorg Chem; 2011 Jan; 16(1):45-50. PubMed ID: 20821241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules.
    Hanif M; Nazarov AA; Legin A; Groessl M; Arion VB; Jakupec MA; Tsybin YO; Dyson PJ; Keppler BK; Hartinger CG
    Chem Commun (Camb); 2012 Feb; 48(10):1475-7. PubMed ID: 22003496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
    Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
    Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis.
    Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F
    Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of selective organoruthenium inhibitors of protein tyrosine phosphatase 1B.
    Ong JX; Yap CW; Ang WH
    Inorg Chem; 2012 Nov; 51(22):12483-92. PubMed ID: 23121648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
    Wang Z; Qian H; Yiu SM; Sun J; Zhu G
    J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors.
    Ma CC; Liu ZP
    Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Organometallic compounds with biological activity: a very selective and highly potent cellular inhibitor for glycogen synthase kinase 3.
    Atilla-Gokcumen GE; Williams DS; Bregman H; Pagano N; Meggers E
    Chembiochem; 2006 Sep; 7(9):1443-50. PubMed ID: 16858717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An organoruthenium complex overcomes ABCG2-mediated multidrug resistance via multiple mechanisms.
    Zeng L; Li J; Zhang C; Zhang YK; Zhang W; Huang J; Ashby CR; Chen ZS; Chao H
    Chem Commun (Camb); 2019 Mar; 55(26):3833-3836. PubMed ID: 30869688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Ru-arene Complexes for Antitumor Drugs.
    Su W; Li Y; Li P
    Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
    Foster P; Yamaguchi K; Hsu PP; Qian F; Du X; Wu J; Won KA; Yu P; Jaeger CT; Zhang W; Marlowe CK; Keast P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Engell K; Bentzien F; Lam ST; Dale S; Yturralde O; Matthews DJ; Lamb P; Laird AD
    Mol Cancer Ther; 2015 Apr; 14(4):931-40. PubMed ID: 25637314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
    He R; Xu B; Ping L; Lv X
    Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
    Wallin JJ; Edgar KA; Guan J; Berry M; Prior WW; Lee L; Lesnick JD; Lewis C; Nonomiya J; Pang J; Salphati L; Olivero AG; Sutherlin DP; O'Brien C; Spoerke JM; Patel S; Lensun L; Kassees R; Ross L; Lackner MR; Sampath D; Belvin M; Friedman LS
    Mol Cancer Ther; 2011 Dec; 10(12):2426-36. PubMed ID: 21998291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
    Ji L; Zheng W; Lin Y; Wang X; Lü S; Hao X; Luo Q; Li X; Yang L; Wang F
    Eur J Med Chem; 2014 Apr; 77():110-20. PubMed ID: 24631730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
    Smith MC; Mader MM; Cook JA; Iversen P; Ajamie R; Perkins E; Bloem L; Yip YY; Barda DA; Waid PP; Zeckner DJ; Young DA; Sanchez-Felix M; Donoho GP; Wacheck V
    Mol Cancer Ther; 2016 Oct; 15(10):2344-2356. PubMed ID: 27439478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arene ruthenium complexes as anticancer agents.
    Süss-Fink G
    Dalton Trans; 2010 Feb; 39(7):1673-88. PubMed ID: 20449402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
    Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.